Hosted on MSN
AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes
AstraZeneca released full results from two successful late-stage trials on its experimental drug for chronic obstructive pulmonary disease. The detailed data reinforces hopes that the product could be ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The Biologics License Application for tozorakimab 300mg, administered once every four weeks, has been accepted for Priority Review by the US Food and Drug Administration as an add-on maintenance ...
AstraZeneca gets a Buy rating as its core business is still growing while a deep late-stage pipeline gives investors multiple ways for earnings. Click for more.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
AstraZeneca's trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?
AstraZeneca posted a rare clinical trial failure on Thursday, sending shares down 6% to their worst day in over two years. Analysts estimate the trial miss wiped just 2-4% from their valuation models ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results